Etienne Rouleau

2.2k total citations · 1 hit paper
39 papers, 547 citations indexed

About

Etienne Rouleau is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Etienne Rouleau has authored 39 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cancer Research, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Etienne Rouleau's work include Cancer Genomics and Diagnostics (23 papers), Genetic factors in colorectal cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Etienne Rouleau is often cited by papers focused on Cancer Genomics and Diagnostics (23 papers), Genetic factors in colorectal cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Etienne Rouleau collaborates with scholars based in France, United Kingdom and Italy. Etienne Rouleau's co-authors include Nicola Normanno, Sabine Merkelbach‐Bruse, Fernando López‐Ríos, John Longshore, Frédérique Penault‐Llorca, Reinhard Büttner, Ludovic Lacroix, Florence Koeppel, Fabrice André and Cécile Jovelet and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Etienne Rouleau

30 papers receiving 544 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Implementing TMB measurement in clinical practice: considerations on assay requirements

2019 247 citations Reinhard Büttner, John Longshore et al. ESMO Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Etienne Rouleau France	11	303	291	219	131	120	39	547
Hongfei Gao China	14	260 0.9×	203 0.7×	174 0.8×	96 0.7×	121 1.0×	52	536
Fabiana Bettoni Brazil	15	273 0.9×	173 0.6×	149 0.7×	247 1.9×	88 0.7×	30	557
Elisabeth Janschek Austria	10	318 1.0×	205 0.7×	125 0.6×	123 0.9×	73 0.6×	17	687
Zaida Morante Peru	11	266 0.9×	142 0.5×	140 0.6×	149 1.1×	37 0.3×	38	479
Ninad Dewal United States	6	194 0.6×	305 1.0×	206 0.9×	228 1.7×	75 0.6×	9	514
Э. Э. Топузов Russia	9	376 1.2×	241 0.8×	150 0.7×	79 0.6×	123 1.0×	39	583
Samuel Suzuki United States	9	228 0.8×	102 0.4×	130 0.6×	214 1.6×	65 0.5×	22	460
Julianna Supplee United States	9	270 0.9×	485 1.7×	334 1.5×	216 1.6×	121 1.0×	13	708
Wolfram Jäger Germany	12	365 1.2×	191 0.7×	68 0.3×	123 0.9×	58 0.5×	25	616
Stefan Kommoss Germany	6	147 0.5×	191 0.7×	121 0.6×	155 1.2×	191 1.6×	10	718

Countries citing papers authored by Etienne Rouleau

Since Specialization

Citations

This map shows the geographic impact of Etienne Rouleau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Etienne Rouleau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Etienne Rouleau more than expected).

Fields of papers citing papers by Etienne Rouleau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Etienne Rouleau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Etienne Rouleau. The network helps show where Etienne Rouleau may publish in the future.

Co-authorship network of co-authors of Etienne Rouleau

This figure shows the co-authorship network connecting the top 25 collaborators of Etienne Rouleau. A scholar is included among the top collaborators of Etienne Rouleau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Etienne Rouleau. Etienne Rouleau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paci, Angélo, et al.. (2025). Pharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond. Bulletin du Cancer. 112(11). 1301–1317.

Torlakovic, Emina, Raed Al Dieri, Tony Badrick, et al.. (2025). Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 487(3). 565–572. 1 indexed citations

Blanc‐Durand, Félix, Damien Vasseur, Audrey Le Formal, et al.. (2024). An evaluation of cell-free tumor DNA from 20 mL of peritoneal fluid for homologous recombination deficiency (HRD) testing in newly diagnosed ovarian cancer (OC).. Journal of Clinical Oncology. 42(16_suppl). 5577–5577. 1 indexed citations

Nicolle, Rémy, Valérie Boige, T. Pudlarz, et al.. (2023). Precision medicine for KRAS wild-type pancreatic adenocarcinomas. European Journal of Cancer. 197. 113497–113497. 16 indexed citations

Blanc‐Durand, Félix, Etienne Rouleau, Antoine Vasseur, et al.. (2023). PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches. A44.1–A44.

Blanc‐Durand, Félix, Christopher M. Kramer, Etienne Rouleau, et al.. (2023). 788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches. Annals of Oncology. 34. S529–S530.

Guerrini‐Rousseau, Léa, Éric Pasmant, Martine Muleris, et al.. (2023). Neurofibromatosis type 1 mosaicism in patients with constitutional mismatch repair deficiency. Journal of Medical Genetics. 61(2). 158–162. 4 indexed citations

Selle, Frédèric, Florence Joly, Laurence Gladieff, et al.. (2023). Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022. Bulletin du Cancer. 110(6). 6S5–6S9.

Mathieu, Marie‐Christine, et al.. (2022). Diagnostic Challenges and Pitfalls of Mammary Pleomorphic Adenoma Illustrated by a Case Report. International Journal of Surgical Pathology. 31(4). 472–477.

10.

Riudavets, Mariona, Damien Vasseur, Édouard Auclin, et al.. (2022). Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer. 23(6). e377–e383. 1 indexed citations

11.

Cotteret, Sophie, et al.. (2022). Malignant Adenomyoepithelioma of the Breast: An Unexpected Malignancy in a Lynch Syndrome Patient. International Journal of Surgical Pathology. 31(5). 572–575.

12.

Martín-Romano, Patricia, Léo Colmet‐Daage, Daphné Morel, et al.. (2022). Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. European Journal of Cancer. 173. 133–145. 1 indexed citations

13.

Bayle, Arnaud, Sophie Cousin, Lola‐Jade Palmieri, et al.. (2022). Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).. Journal of Clinical Oncology. 40(16_suppl). 3016–3016.

14.

Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. Journal of Clinical Oncology. 40(16_suppl). 5571–5571. 2 indexed citations

15.

Ferlicot, Sophie, Pierre‐Alexandre Just, Éva Compérat, et al.. (2021). Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report. Diagnostic Pathology. 16(1). 107–107. 3 indexed citations

16.

Koeppel, Florence, Etienne Müller, Alexandre Harlé, et al.. (2021). Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies. European Journal of Cancer. 159. 1–15. 10 indexed citations

17.

Boilève, Alice, Armelle Dufresne, Ali N. Chamseddine, et al.. (2020). Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open. 5(6). e001082–e001082. 2 indexed citations

18.

Remón, Jordi, Aurélie Swalduz, David Planchard, et al.. (2020). Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE. 15(6). e0234302–e0234302. 14 indexed citations

19.

Büttner, Reinhard, John Longshore, Fernando López‐Ríos, et al.. (2019). Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 4(1). e000442–e000442. 247 indexed citations breakdown →

20.

Koeppel, Florence, Steven G. Blanchard, Cécile Jovelet, et al.. (2017). Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS ONE. 12(11). e0188174–e0188174. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact